<?xml version="1.0" encoding="UTF-8"?>
<p id="Par68">During active COVID-19, the immunosuppressive therapy was discontinued in most rheumatology patients [
 <xref ref-type="bibr" rid="CR29">29</xref>, 
 <xref ref-type="bibr" rid="CR32">32</xref>–
 <xref ref-type="bibr" rid="CR35">35</xref>]. Another important topic is when to re-initiate these therapies. In the case reports Song et al. [
 <xref ref-type="bibr" rid="CR35">35</xref>] and Mihai et al. [
 <xref ref-type="bibr" rid="CR33">33</xref>], the immunosuppressive therapies were re-initiated 2–4 days after a negative test result for COVID-19. In their expert opinion article, Sarzi-Puttini et al. suggested that these drugs should be re-initiated only after two negative swabs [
 <xref ref-type="bibr" rid="CR157">157</xref>].
</p>
